Admission of Conditional Placing Shares

Admission of Conditional Placing Shares

Oxford, UK - 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the "Company"), a leading gene and cell therapy group, confirms that 5,018,134 new ordinary shares (the "Conditional Placing Shares") have this morning been admitted to the premium listing segment of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the main market for listed securities of London Stock Exchange plc.

The Conditional Placing Shares were subscribed for at an issue price of 810 pence per share and have raised gross proceeds of circa £40.6 million for the Company and represented approximately 5.5% of the Company's issued share capital as at the last practicable date prior to the posting of the Circular on 16 February 2022.

Total Voting Rights

Following Admission of the Conditional Placing Shares in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued share capital as at 8:00 am on 11 March 2022 consisted of 96,062,640 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 96,062,640.

The above figure 96,062,640 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules. 

Enquiries:

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

Peel Hunt (Sponsor and Joint Bookrunner): T: +44 (0)20 7418 8900

James Steel

Jock Maxwell Macdonald

Sohail Akbar

WG Partners (Joint Bookrunner): T: +44 (0)20 3705 9330

David Wilson

Claes Spång

Satheesh Nadarajah

Consilium Strategic Communications:

Mary-Jane Elliott T: +44 (0)7739 788 014

Matthew Neal T: +44 (0)7720 088 468

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com.